Can Sponsors Respond by Finding Non-Responders?
This article was originally published in RPM Report
One way to get a more favorable review from FDA is to find products that work on a well-defined, under-served patient populations. Wyeth R&D head Robert Ruffolo has some questions about how difficult it will be for sponsors to find those populations. Here is what he had to say about the difficult time-frame for taking a non-responder strategy.
You may also be interested in...
Trump Administration’s attempt to eliminate rebates in the US Medicare outpatient drug benefit program is the easiest and most certain item among the 11th hour pricing policy changes for the incoming Biden Administration to undo. But it still had a major impact on the dynamics of the drug pricing debate.
Multiple simultaneous sponsors, foreshortened regulatory reviews, and a packet of unanswered post-approval efficacy issues make for what should be very competitive – and inherently comparative – post-market assessment period for the upcoming SARS-CoV-2 vaccines.
US FDA asks oncology drug sponsors for information on the impact of modifications to clinical trials during the pandemic – with close attention to remote monitoring and data collection.